CYTK Share Price Performance
US$77.13
40.44 (110.22%)
28.5% undervalued intrinsic discount
US$107.80
Fair Value
Price US$77.13
AnalystConsensusTarget US$107.80
AnalystLowTarget US$83.00
AnalystHighTarget US$136.89
Fair ValueUS$107.80
Share Pricen/a
Cytokinetics, Incorporated Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 20 Fair Values set on narratives written by author
CYTK Community Narratives
AN
Fair Value
·Fair Value US$107.8 28.5% undervalued intrinsic discount
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$83 7.1% undervalued intrinsic discount
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$136.89 43.7% undervalued intrinsic discount
Aging Global Population Will Boost HCM Therapy Uptake
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Cytokinetics is betting big on an upcoming heart drug launch, backed by encouraging trial results, a built-out sales team, and partners that can help it reach patients worldwide. The catch is it still needs key approvals and faces tough competition and high spending, so a delay or slow doctor and insurer adoption could quickly change the outlook.Read more
AN
US$107.8
28.5% undervalued intrinsic discount
Fair Value
Profit Margin
17.18%
Future PE
103.57x
Price in 2029
US$132.4
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
Cytokinetics is pushing a promising heart-focused drug toward the finish line, but the biggest slowdown may come after approval as insurers and country-by-country payment decisions drag out the rollout. If the company can navigate that red tape without needing too much new funding, it could still build a broader set of treatments—yet setbacks with its lead drug or stronger rivals could quickly change the story.Read more
AN
US$83
7.1% undervalued intrinsic discount
Fair Value
Profit Margin
18.76%
Future PE
89.08x
Price in 2029
US$102.01
Aging Global Population Will Boost HCM Therapy Uptake
A little-known heart drug could quickly move from “promising” to a go-to option as new study results shake up how doctors treat a hard-to-manage condition. But the upside comes with big risks, including reliance on one lead program, possible approval delays, and rising costs as rivals crowd the field.Read more
AN
US$136.89
43.7% undervalued intrinsic discount
Fair Value
Profit Margin
18.98%
Future PE
96.7x
Price in 2029
US$168.22
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
CYTK: Myqorzo Launch Adoption And ACACIA HCM Expansion Will Drive Upside
Fair Value: US$107.8 28.5% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CYTK: Future Returns Will Rely On HCM Execution And Phase 3 Outcomes
Fair Value: US$83 7.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CYTK: HCM Launch And ACACIA Phase 3 Readout Will Drive Repricing
Fair Value: US$136.89 43.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cytokinetics, Incorporated Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- -6.11
- -290.73%
- -784.02%
- -159.4%
About CYTK
- Founded
- 1997
- Employees
- 673
- CEO
- WebsiteView website
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
